443 related articles for article (PubMed ID: 20697298)
1. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
2. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
3. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
[TBL] [Abstract][Full Text] [Related]
4. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
[TBL] [Abstract][Full Text] [Related]
5. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
Wang X; Wang G; Hao Y; Xu Y; Zhang L
Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
[TBL] [Abstract][Full Text] [Related]
6. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
8. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
[TBL] [Abstract][Full Text] [Related]
9. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
[TBL] [Abstract][Full Text] [Related]
10. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
11. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D
Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143
[TBL] [Abstract][Full Text] [Related]
14. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
15. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y
Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemistry using epidermal growth factor receptor mutation-specific antibodies of delE746-A750 and L858R in lung adenocarcinomas].
Fan XS; Liu B; Yu B; Shi SS; Wang X; Zhang J; Wang JD; Lu ZF; Ma HH; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):173-7. PubMed ID: 23769436
[TBL] [Abstract][Full Text] [Related]
19. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
20. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
